Month: September 2026

To Nasdaq Copenhagen A/S	25. September 2026
	Announcement no. 82/2026

Correction: The end dates of the stated interest rate periods in the published company announcement were incorrectly specified. The interest rates apply until and including the last day of the respective interest rate periods (the end of the relevant calendar quarter), not the first day of the subsequent calendar quarter. All other information remains unchanged.

Fixing of Coupon Interest Rate

Interest rate for Jyske Realkredit’s:

Series BRF454BOA 38 with ISIN DK0009361628 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154B 38 with ISIN DK0009361701 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154E 41 with ISIN DK0009366932 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series BRF454EOA 41 with ISIN DK0009367070 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series 422.E.OA Cb3.ju27 RF with ISIN DK0009412207 has per 1 October 2026 and until and including 1 January 2027 been set at 2.91 % p.a.

Series G-422.E.OA Cb3.ju27 RF with ISIN DK0009412397 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series 422.B.OA Cb3.ju27 RF with ISIN DK0009412470 has per 1 October 2026 and until and including 1 January 2027 been set at 3.00 % p.a.

Series G422.E.OA Cb3.ju27 RF with ISIN DK0009414682 has per 1 October 2026 and until and including 1 January 2027 been set at 2.76 % p.a.

Series 422.E.OA Cb3.ju28 RF with ISIN DK0009414765 has per 1 October 2026 and until and including 1 January 2027 been set at 2.79 % p.a.

Series 422.E.OA Cb3.ju29 RF with ISIN DK0009417198 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series G422.E.OA Cb3 ju29 RF with ISIN DK0009417271 has per 1 October 2026 and until and including 1 January 2027 been set at 2.85 % p.a.

Series 422.E.OA Cb3.ju30 RF with ISIN DK0009419137 has per 1 October 2026 and until and including 1 January 2027 been set at 2.62 % p.a.

Series SNP322.ap.28 with ISIN DK0009417008 has per 1 October 2026 and until and including 1 January 2027 been set at 3.23 % p.a.

Questions may be addressed to Christian Bech-Ravn, tel. (+45) 89 89 92 25.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

CALGARY, Alberta, Sept. 29, 2026 (GLOBE NEWSWIRE) — Esker Infrastructure Corp. (formerly Cielo Waste Solutions Corp.) (TSXV: CMC; OTCQB: CWSFF) (“Esker” or the “Company”) is pleased to announce it has changed its name to Esker Infrastructure Corp. (“Esker”), effective September 25, 2026, marking the final step in a year-long strategic transformation from a technology developer into a project developer. The name change reflects the Company’s previously disclosed strategic direction and business activities — specifically, its deliberate shift away from developing proprietary technology and toward originating, structuring, and financing infrastructure projects built on proven, third-party technologies.

The TSX Venture Exchange (“TSXV”) has conditionally approved the Company’s name change. The Company expects its common shares to begin trading on the TSXV under the new name and ticker symbol “ESKR” and on the OTCQB under the ticker symbol “ESKRF” at the opening of trading on October 2, 2026. The Company’s new CUSIP number will be 29643A109 and its new ISIN will be CA29643A1093. The Company’s listed common share purchase warrants issued in July 2022 and expiring in July 2027 are expected to begin trading under the new symbol “ESKR.WT” also at the opening of trading on October 2, 2026. The warrants will have the new CUSIP number 29643A117 and ISIN CA29643A1176.

Why Esker

An esker is a ridge formed by water flowing beneath a glacier that creates a durable path through the landscape – a structure that outlasts the system that created it.

“Our new name reflects our strategy,” said Ryan C. Jackson, Chief Executive Officer. “We are a company that originates, structures and finances long-term, low-carbon energy infrastructure. We develop projects that are built to last.”

Esker’s Strategy

Over the past year, the Company has systematically repositioned its business model to focus on project origination and development rather than technology innovation. This transition has been supported by a renewed executive team and Board of Directors, a risk-gated framework for capital deployment, and a disciplined project development process designed to support sustainable, long-term growth. Together, these changes represent a comprehensive realignment of the Company’s strategy, governance and operational approach. The name change is the final chapter in that transition.

Esker’s inaugural project, Project Nahoonai, is expected to be executed in several phases across multiple sites in British Columbia, subject to meeting the criteria required to structure a financeable project at each site and is currently in a pre-final investment decision (“FID”) stage.

“The name change is a change in identity, not in direction,” added Mr. Jackson. “The strategy that has guided our recent executive and Board appointments — building the team and the platform needed to originate, structure and finance a pipeline of projects.”

No Action Required

The name change will not result in a change to the Company’s business, affairs or issued and outstanding share capital. Existing share certificates representing common shares of the Company are expected to remain valid and shareholders are not expected to be required to exchange their share certificates.  

Other than the change in the Company’s name and trading symbols described above, shareholders are not required to take any action as a result of the name change.

ABOUT ESKER

Esker Infrastructure Corp. (formerly Cielo Waste Solutions Corp.) is a project development company advancing sustainable aviation fuel and other low-carbon energy projects. Esker combines strategic feedstock partnerships with proven third-party technologies to develop a scalable pipeline of waste-to-fuels projects, anchored by its flagship Project Nahoonai in British Columbia.

For further information, please contact:
Esker Investor Relations
Ryan C. Jackson, Chief Executive Officer
Phone: (403) 348-2972
Email: investors@eskercorp.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain certain forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements regarding the approval of the TSXV, the anticipated commencement of trading of the Company’s common shares and share purchase warrants under its new name and trading symbols, the continued validity of existing share certificates and whether shareholders will be required to exchange their share certificates, the Company’s leadership team, the Company’s continued transition to, and implementation of, its business model as a project developer and low-carbon energy infrastructure platform, the Company’s business strategy, including the origination, structuring, financing and development of a portfolio of waste-to-fuels and other low-carbon energy projects, the development and execution of Project Nahoonai in multiple phases and across multiple sites in British Columbia; the satisfaction of the criteria required to structure a financeable project at each site; the advancement of multiple sites, sustainable, long-term growth, and the Company’s project pipeline.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors, many of which are beyond the control of the Company, that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Management to Discuss TruGolf’s Golf Technology Business and Proposed Acquisition of Polymath

SALT LAKE CITY, Utah, and TORONTO, Canada, Sept. 29, 2026 (GLOBE NEWSWIRE) — TruGolf Holdings, Inc. (NASDAQ: TRUG) (“TruGolf” or the “Company”) today announced that Brenner Adams, Chairman and Interim CEO of TruGolf, and Natalie Hirsch, Interim CEO and CFO of Polymath Research Inc. (“Polymath”), will present at The ThinkEquity Conference on Thursday, Oct. 15, 2026, at the Mandarin Oriental in New York.

Management will discuss TruGolf’s golf technology business, including the TruGolf Links franchise model, and the Company’s expansion into tokenized financial infrastructure through its acquisition of Polymath. Management will also hold one-on-one meetings with investors throughout the day.

“New York is the right room for this story,” said Natalie Hirsch. “We look forward to walking investors through how Polymath’s institutional tokenization infrastructure and TruGolf’s established golf technology business fit together, and where we’re taking the combined company.”

Investors interested in meeting with management may contact their ThinkEquity representative or ThinkEquity Corporate Access at corporateaccess@think-equity.com

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. These statements relate to future events, future expectations, plans and prospects. Although the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

About TruGolf

Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf’s mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology – because TruGolf believes Golf is for Everyone. TruGolf’s team has built award-winning video games (“Links”), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6. Since TruGolf’s beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology.

About Polymath

Polymath is a privately held Canadian technology company that develops enterprise-grade capital markets infrastructure for the issuance, compliance, and lifecycle management of regulated digital securities and other tokenized financial instruments for private and institutional markets.

Investor Contact: Michael Bacal, mbacal@darrowir.com, 917-886-9071
Media Contact: David Cash, david.cash@polymath.network, +1 416 877 2562

Initial order potential first step to a multi-year deployment program.

GARDENA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Polar Power, Inc. (Nasdaq: POLA) (“Polar” or the “Company”), a designer and manufacturer of high-efficiency DC power systems for telecom and other mission-critical applications, today announced it has received a trial order for 50 propane-fueled DC generators from a major Tier 1 telecom operator in Southeast Asia. The generators will power off-grid and bad-grid cell sites.

The trial is the first phase of a potential five-year program that could cover approximately 2,500 of the customer’s sites. Discussions between the Company and this customer have begun on the next phase of 200 propane generators. The customer has not committed to broader deployment. If it proceeds, and based on current estimated system pricing, the opportunity could represent up to approximately $60 million in revenue over five years. Polar’s DC Generator ranges from $19,000 to $27,000 each depending on accessories and service options.

The order follows the Company’s more than five years of work with telecom operators in the Asia-Pacific region, including vendor qualification, multiple rounds of technical evaluation, field testing, and operational reviews.

According to the TowerXchange’s Q2 2024 Asia Guide there are 426,967 telecom towers/sites across the eight Southeast Asian markets.

“This order is an important step toward modernizing telecom power with LPG and DC systems,” said Arthur D. Sams, Chief Executive Officer of Polar. “We believe the combination of economic and environmental benefits will attract other operators and LPG distributors, whose participation could help accelerate our sales. Our expectation is that orders from other Telecom companies in this region will take months to close as opposed to years due to the large energy savings especially with the rising cost and theft of diesel fuel.”

Product and expected benefits

Polar’s DC generator combines its Supra^™ system controls and a high-efficiency permanent magnet alternator with Toyota 1KS prime power engines. Based on field experience, the Company estimates that:

• Fuel: The system uses approximately 40% less fuel than diesel AC generator solutions without solar. Paired with solar, savings have been demonstrated at 59% and higher.
• Maintenance: The oil change interval is approximately 4,500 hours, versus approximately 250 hours for standard diesel AC gensets, which reduces the cost of site visits.
• Operating cost: Because fuel is a large share of operating expense at off-grid and bad-grid sites, fuel savings has a meaningfully impact on lowering total site OPEX.

Supply readiness

Given long engine lead times, Polar has purchased approximately 2,000 Toyota 1KS engines to support potential volume growth. The Company previously wrote down approximately $4 million of usable engine inventory, and expects that using this inventory may support improved margins as volumes ramp. Polar’s large inventory of Toyota 1KS engines should help facilitate a rapid delivery of generators into emerging markets.

The economics is driving the sale

1. Fuel Savings. During the field trails Polar demonstrated 40% fuel savings. From field observation, diesel cost per site ranges from $960 to $2,400 per month. The estimated diesel cost does not include theft in the region of 15% to 25%. The net savings at 40% is $384 to $960 a month. Assuming a deployment of 2,500 sites, the annual saving ranges from $11M to $28M with Polar DC generators.
2. Maintenance savings. Scheduled maintenance service for a Diesel AC generator is 200 to 250 hours; so, running 12 to 24 hours a day will require 18 to 36 service trips a year. The Polar DC generator with the Toyota engine has a scheduled service maintenance of 4,500 hours requiring a maximum of 2 visits a year running 24 hours a year. The Company estimates that the cost is $100 to $150 per site visit for a Diesel AC generator, totaling between $1,800 to $5,400 per year per site, while maintaining a Polar DC generator costs $600 per year running 24/7. Assuming a deployment of 2,500 sites, the annual saving ranges from $3M to $12M with Polar DC generator.

Broader LPG opportunity

In addition, a major local LPG distributor expects to receive a contract from its customer to fuel each site for 6 years. Our telecom customer was concerned with getting propane to each site and the participation of a major LPG distributor was essential to the program success. The LPG distributor will benefit with a substantial increase in revenues as new wave of opportunity opens with power generation using LPG in place of diesel.

About Polar Power, Inc.

Polar Power, Inc. (NASDAQ: POLA) designs, manufactures and sells direct-current power generators, renewable energy systems and other power solutions for applications including telecommunications, drone defense, robotics, EV charging, micro-grids military and commercial markets. The Company is headquartered in Gardena, California.

For more information, please visit www.polarpower.com. or follow Polar Power on www.linkedin.com/company/polar-power-inc/.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the potential size, timing, and revenue of a broader deployment, customer adoption, expected fuel and cost savings, LPG distributor participation, and future margins. These statements involve risks and uncertainties, including but not limited to that the customer may not proceed beyond the trial, delays in telecom adoption cycles, pricing and competition, supply chain and inventory risks, and other factors described in the Company’s SEC filings, including its most recent Form 10-K and 10-Q. Actual results may differ materially. The Company undertakes no obligation to update these statements except as required by law.

Media and Investor Relations
Polar Power, Inc.
249 E. Gardena Blvd.
Gardena, CA 90248
Tel: 310-830-9153
Email: ir@polarpowerinc.com
www.polarpower.com

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~ 

~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011) ~ 

 ~ Treatment effect at 48 months likely understated by substantial missing data and survivor bias in updated external control; post hoc analysis using prior external control showed slowing of disease of 54% on cUHDRS (nominal p=0.041) and 68% on TFC (nominal p=0.001) at 48 months ~

~ These positive data are meaningful for Huntington’s disease patients who currently have no approved disease-modifying treatment options ~

~ Investor conference call and webcast today at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

“Four years after a single administration, ifezuntirgene inilparvovec continues to show meaningful slowing of disease progression, further strengthening our conviction in its benefit for people living with Huntington’s disease,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “At 48 months, Total Functional Capacity (TFC), the primary measure of our confirmatory study, demonstrated consistent slowing of functional decline, with the absolute treatment benefit maintained in Month 48. Furthermore, the observed differences between the high and low doses on both composite Unified Huntington’s Disease Rating Scale (cUHDRS) and TFC are consistent with a dose-dependent treatment effect. The updated 36-month analysis, which now includes three additional high-dose patients, showed a substantial effect on cUHDRS and TFC, further reinforcing the data included in our license applications. We believe these data are clinically meaningful for Huntington’s disease patients, and we look forward to presenting them at a future scientific meeting.”

Topline Clinical Data at 36 months and 48 months¹

Today’s announcement comprises results from the ongoing Phase I/II studies at two timepoints, with a data cutoff of June 30, 2026. Twenty-nine patients have been treated with ifezuntirgene inilparvovec (n=17 high dose; n=12 low dose) across the studies’ first two cohorts. The new 36-month analysis now includes 15 high-dose and 12 low-dose patients, with three additional high-dose patients having reached that timepoint since the September 2025 analysis. The 48-month analysis includes 12 patients at each dose.

Outcomes for the 36-month and 48-month analyses were compared to propensity score-matched external controls (n=1,337 for high dose) from an updated ENROLL-HD natural history dataset with a September 2025 cutoff. As is common with longitudinal natural history studies, missingness of data increased with duration of follow-up, reaching 53% in the updated ENROLL-HD matched controls at 48 months. The Company’s analysis of the updated control showed that patients discontinuing follow-up were progressing materially faster than those remaining in the control group. The Company believes these factors likely understated disease progression in the control and the resulting treatment effect of ifezuntirgene inilparvovec at 48 months.

At the June 2026 Type B meeting, the FDA communicated that the 36-month data from 12 high-dose patients would be acceptable as the primary basis for the BLA submission under the accelerated approval pathway, and the submission was made accordingly. The BLA submission of ifezuntirgene inilparvovec predated the topline results announced today and these results were not part of the submission.

High-Dose Results at 36 Months (n=15)

• cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients had a mean change in cUHDRS from baseline of -0.28 compared to a change of -1.39 for the external control, a favorable treatment difference of 1.12 compared to baseline.

• TFC showed 67% slowing of disease progression compared to the updated external control (nominal p=0.011). Treated patients had a mean change in TFC from baseline of -0.27 compared to a change of -0.82 for patients in the propensity score-matched external control, a favorable treatment difference of 0.55 compared to baseline.
• Mean cerebrospinal neurofilament light protein (CSF NfL) was 6% below baseline (n=14).

High-Dose Results at 48 Months (n=12)

• cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Treated patients had a mean change in cUHDRS from baseline of -0.90 compared to a change of -1.61 for the external control, a favorable treatment difference of 0.71 compared to baseline.
• TFC showed 61% slowing of disease progression compared to the updated external control (nominal p=0.008). Treated patients had a mean change in TFC from baseline of -0.37 compared to a change of -0.94 for the external control, a favorable treatment difference of 0.57 compared to baseline.
• In a post-hoc sensitivity analysis using the prior ENROLL-HD external control, the 48-month analysis showed 53.5% slowing based on cUHDRS (nominal p=0.041) and 68.3% based on TFC (nominal p=0.001).
• Mean cerebrospinal neurofilament light protein (CSF NfL) was 4% above baseline (n=11).

Dose Comparison at 48 Months (high dose n=12, low dose n=12)

• The observed differences between the high and low doses are consistent with a dose-dependent treatment effect. At 48 months, mean change from baseline in cUHDRS was –0.91 in high-dose patients compared with −1.94 in low-dose patients, a difference of 1.03 in favor of the high dose. Mean change from baseline in TFC was −0.30 in high-dose patients compared with −0.70 in low-dose patients, a difference of 0.40 in favor of the high dose.

“Huntington’s disease does not slow on its own; the biology is one of inevitable progressive decline,” stated Victor Sung, M.D., professor of neurology at the University of Alabama at Birmingham (UAB), director of the UAB Huntington’s Disease Clinic. “What I find particularly notable in the expanded data is the consistently meaningful treatment effect at 36 months, and the apparent stability of the functional capacity benefit through Month 48. We see this even as the rate of decline in the updated comparator dataset slowed, an anticipated shift which appears to reflect some attrition in the longitudinal external control data, and which does not reflect the typical clinical presentation of accelerating decline over time. Total Functional Capacity tracks things that matter the most to patients and families – ability to work, perform household chores and handle daily self-care activities. Seeing that treatment difference maintained at four years is meaningful for people living with this relentlessly progressive degenerative disease.”

Ifezuntirgene inilparvovec continues to be generally well-tolerated, with a manageable safety profile at both doses. The most common adverse events in the treatment groups were related to the administration procedure, and all have resolved. As previously disclosed, five high dose participants (17%) experienced a treatment-related serious adverse event (SAE) related to central nervous system inflammation, all of which fully resolved.

Since the September 2025 data readout, one suicide in a low-dose patient occurred, approximately five years after receiving treatment. This was assessed as unrelated to treatment by the study investigator. Suicidal ideation and completed suicide occur at substantially elevated rates in Huntington’s disease relative to the general population, and suicide is among the leading causes of death in those with the disease.

Investor Conference Call and Webcast Information 

uniQure management will host an investor conference call and webcast today, Tuesday, September 29 at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE^® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.², EU³, and the UK⁴, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “establish,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions and the negatives of those terms. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the factors that likely understate disease progression in the updated ENROLL-HD controls and the Company’s belief that ifezuntirgene inilparvovec meaningfully reduces disease progression based on its evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/II clinical trials of ifezuntirgene inilparvovec, including the risk that such trials will be unable to continue to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that the FDA ultimately concludes that the Phase I/II trial data are not sufficient to support a BLA or accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC“), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:
FOR INVESTORS:	FOR MEDIA:
Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com	Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com

¹ cUHDRS is the pre-specified primary endpoint for the 48 months analysis; all other p-values are nominal. The 36-month data included 15 high-dose patients; the 48-month analysis included 12 high-dose patients. Percentage slowing was sensitive to the magnitude of decline in the external control.
² Yohrling G, et al. Neurology 2020;94(15 Suppl):954.
³ Medina A, et al. Mov Disord 2022;37(12):2327–2335
⁴ Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.

Milestone Marks Recombinant Spider Silk’s Move from Scaled Production to a First-of-Its-Kind Performance Textile

ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the shipment of its first commercial order of recombinant spider silk yarn. The custom-engineered yarn was produced to fulfill a purchase commitment from a globally recognized performance sports brand and is slated for development into a first-of-its-kind performance textile.

This spider silk sale is part of a confidential pilot development program. The program targets one of the most demanding and innovation-focused segments of the athletic apparel market. The yarn has been custom processed to the customer’s specifications and has now shipped.

“Completing the delivery of this spider silk yarn is a huge milestone for Kraig Labs,” said Kim Thompson, Founder and CEO of Kraig Labs. “The volume is small by design. This is a precision application, not a bulk order. It is exactly the kind of application where spider silk’s real advantages can be highlighted. Strength, flexibility, toughness, and light weight, under conditions pushing materials to their limits. This application is a shining example of how spider silk can transform markets.”

The shipment comes at a pivotal moment for the global textile industry, as fashion and performance brands explore new materials while confronting the challenge of moving promising fiber technologies from laboratory innovation to reliable production. Textile Exchange’s Materials Market Report 2026, published September 22, reported that global fiber production reached a record 139 million metric tons in 2025, with polyester accounting for 59% of total output and 88% of polyester production coming from virgin fossil-based sources. Against that backdrop, the opportunity for emerging performance materials is significant, but so is the challenge: new fibers must deliver differentiated properties while proving they can be produced consistently and integrated into an industry built around enormous volumes of established materials. Kraig Labs’ first commercial shipment represents an important step from material innovation and scaled production toward real-world textile adoption.

Kraig Labs views elite performance apparel as one of the clearest proving grounds for recombinant spider silk. A category where gains in strength-to-weight ratio and durability translate directly into competitive advantage for the athlete.

“High-performance sport is where materials prove themselves,” Thompson continued. “Performance wins. That is the only thing that matters in elite sport. It’s about how it performs when everything is on the line, and that’s exactly what we intend to prove.”

While the quantity of silk in this shipment is small, Kraig Labs believes the true significance lies in what it represents for the broader athletic and performance textile market. A successful application here demonstrates that recombinant spider silk can meet the exacting technical standards of elite sport, standards few materials, natural or synthetic, are able to satisfy. A validated performance application of this kind opens the door to further engagement with brands across the performance apparel space.

“This is the kind of project that changes the conversation,” Thompson concluded. “When a brand at this level puts our material to the test, the results speak for themselves. We intend for this to be the first of many.”

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/656da44f-ba1b-467d-81d2-63af7e1d4a8e

https://www.globenewswire.com/NewsRoom/AttachmentNg/8621458d-87fb-47e9-b5e1-aaa6490608da